Pharmaceutical Investing AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Pharmaceutical Investing SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
Pharmaceutical Investing AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
Pharmaceutical Investing AbbVie Announces U.S. FDA Approval of EPKINLY® in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
Pharmaceutical Investing LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer
Pharmaceutical Investing AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
Pharmaceutical Investing Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
Pharmaceutical Investing ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers
Pharmaceutical Investing The One & Only BOTOX® Cosmetic Day Returns November 19 with the Biggest Celebration of the Year
Pharmaceutical Investing AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib in Adults and Adolescents with Vitiligo
Pharmaceutical Investing Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
Pharmaceutical Investing The Confidence Project by BOTOX® Cosmetic Unveils This Year's Grant Recipients
SAGA Metals Completes Phase 2 of Major Drill Program at the Radar Project in Labrador-Confirms Extensive Oxide Mineralization in All Drill Locations at Trapper North and South Zones & Provides Corporate Update
